Abstract
Sacubitril/Valsartan is a safe and effective treatment for heart failure post-AMI, offering significant improvements in cardiac function, inflammatory response, exercise capacity, and a reduction in MACE risk.
Introduction
Acute Myocardial Infarction (AMI) often leads to significant myocardial damage and subsequent heart failure. While Angiotensin-Converting Enzyme Inhibitors (ACEIs) like Benazepril have long been the standard of care for managing the renin-angiotensin-aldosterone system (RAAS), they frequently fail to prevent the structural changes known as ventricular remodeling. This study investigates the efficacy of Sacubitril/Valsartan, an Angiotensin Receptor-Neprilysin Inhibitor (ARNI), which offers a dual mechanism: inhibiting the RAAS while simultaneously enhancing the beneficial natriuretic peptide system.
Methodology
This retrospective analysis included 103 patients treated for post-AMI heart failure at The Third Affiliated Hospital of Qiqihar Medical College between 2021 and 2024. All participants had undergone percutaneous coronary intervention (PCI) and met specific inclusion criteria, including an ejection fraction (LVEF) <50% and elevated NT-proBNP levels (>300µg/L).
Patients were divided into two cohorts:
- Control Group (n=51): Received 10 mg/day of Benazepril.
- Observation Group (n=52): Received Sacubitril/Valsartan, titrated from 50 mg to a target dose of 200 mg twice daily.
Key outcomes measured over a six-month follow-up included echocardiographic parameters, inflammatory biomarkers (hs-CRP, IL-6), and functional capacity via the 6-minute walk distance (6MWD).
Results and Discussion
Enhanced Cardiac Function
The study found that Sacubitril/Valsartan significantly improved cardiac remodeling parameters compared to Benazepril. Specifically, the observation group showed a more pronounced increase in LVEF and a greater reduction in both LVESV and LVEDD, indicating superior reversal of pathological remodeling.
Clinical Efficacy and Safety
The total effective rate was notably higher in the Sacubitril/Valsartan group (94.92%) compared to the Benazepril group (79.31%). Furthermore, the incidence of Major Adverse Cardiac Events (MACE), such as re-hospitalization and arrhythmias, was significantly lower in the observation group (11.54% vs. 31.37%). Importantly, safety profiles were comparable, with no significant difference in adverse reactions like hypotension or dizziness between the two cohorts, suggesting the ARNI is as safe as traditional ACEIs.
Anti-inflammatory and Functional Benefits
Sacubitril/Valsartan treatment led to a more substantial decrease in systemic inflammatory markers (hs-CRP and IL-6) and heart stress markers (NT-proBNP). These physiological improvements translated into better physical capacity, as evidenced by a significantly longer 6-minute walk distance in the observation group compared to the control group.
Conclusion
Sacubitril/Valsartan demonstrates superior clinical efficacy over Benazepril in treating heart failure following AMI. By effectively managing both the RAAS and natriuretic peptide systems, it better addresses ventricular remodeling and reduces the risk of major adverse events. While limited by its retrospective nature and single-center sample size, this study supports the use of ARNIs as a potent therapeutic option for post-AMI recovery. Future large-scale, prospective randomized controlled trials are recommended to further validate these findings.
Summary updated